Figures
![Figure 1.](/tables/wjon1658-g001.jpg)
Figure 1. Histopathological results. Pathological analysis of surgical tissue from (a) breast, (b) uterus, and (c) abdominal tumor.
![Figure 2.](/tables/wjon1658-g002.jpg)
Figure 2. (a, b) Abdominal CT images revealing the multiple abdominal mass (arrows). CT: computed tomography.
![Figure 3.](/tables/wjon1658-g003.jpg)
Figure 3. Examination results for mass in her thoracic cavity by (a) CT, (b) PET-CT (SUVmax = 2.5), and (c) pathological analysis. ER: estrogen receptor; PgR: progesterone receptor; H&E: hematoxylin and eosin stain; CT: computed tomography; PET-CT: positron emission tomography-computed tomography; SUVmax: maximum standardized uptake value.
![Figure 4.](/tables/wjon1658-g004.jpg)
Figure 4. (a, b) PET-CT images showed tumors in pancreas and liver (SUVmax = 4.0 and 4.6, respectively) (arrows). PET-CT: positron emission tomography-computed tomography; SUVmax: maximum standardized uptake value.
![Figure 5.](/tables/wjon1658-g005.jpg)
Figure 5. Pathological analysis of pancreatic tumor tissue. H&E: hematoxylin and eosin stain. ER: estrogen receptor; PgR: progesterone receptor; H&E: hematoxylin and eosin stain; GATA-3: GATA binding protein 3; PAX8: paired box 8; GCDFP15: gross cystic disease fluid protein 15.
![Figure 6.](/tables/wjon1658-g006.jpg)
Figure 6. Transition graph of tumor markers (CA19-9, SPAN-1, and DUPAN-2). GEM+nabPTX: gemcitabine with nab-paclitaxel; DUPAN-2: Duke pancreatic monoclonal antigen type 2; SPAN-1: s-pancreas antigen-1; CA19-9: carbohydrate antigen 19-9.
![Figure 7.](/tables/wjon1658-g007.jpg)
Figure 7. Distribution of MPMNs with breast cancer patients. (a) Synchronous vs. metachronous. (b) Breast cancer onset timing. (c) Comorbid cancer. MPMNs: multiple primary malignant neoplasms; GIST: gastrointestinal stromal tumor.